BESPONSA™ Highlights

(inotuzumab ozogamicin)

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use BESPONSA™ safely and effectively. See full prescribing information for BESPONSA.

BESPONSA (inotuzumab ozogamicin) for injection, for intravenous use
Initial U.S. Approval: 2017

WARNING: HEPATOTOXICITY, INCLUDING HEPATIC VENO-OCCLUSIVE DISEASE (VOD) (ALSO KNOWN AS SINUSOIDAL OBSTRUCTION SYNDROME) and INCREASED RISK OF POST- HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) NON-RELAPSE MORTALITY

See full prescribing information for complete boxed warning.

•
Hepatotoxicity, including fatal and life-threatening VOD occurred in patients who received BESPONSA. (5.1)
•
A higher post-HSCT non-relapse mortality rate occurred in patients receiving BESPONSA (5.2)

RECENT MAJOR CHANGES

Indications and Usage (1)

3/2024

Dosage and Administration, Instructions for Reconstitution, Dilution and Administration (2.4)

3/2024

Warnings and Precautions, Hepatotoxicity, Including Hepatic Veno-occlusive Disease (VOD) (also known as Sinusoidal Obstruction Syndrome) (5.1)

3/2024

Warnings and Precautions, Increased Risk of Post-Transplant Non-Relapse Mortality (5.2)

3/2024

Warnings and Precautions, Myelosuppression (5.3)

3/2024

Warnings and Precautions, Infusion Related Reactions (5.4)

3/2024

Warnings and Precautions, QT Interval Prolongation (5.5)

3/2024

INDICATIONS AND USAGE

BESPONSA is a CD22-directed antibody and cytotoxic drug conjugate indicated for the treatment of relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients 1 year and older. (1)

DOSAGE AND ADMINISTRATION

•
Administer by intravenous infusion only. (2.1)
•
Pre-medicate with a corticosteroid, antipyretic, and antihistamine prior to all infusions. (2.2)
•
Dosing regimens for Cycle 1 and subsequent cycles, depending on the response to treatment, are shown below. See full prescribing information for dosing details. (2)
*
For patients who achieve a CR or a CRi, and/or to allow for recovery from toxicity, the cycle length may be extended up to 28 days (i.e., 7-day treatment-free interval starting on Day 21).

Day 1

Day 8

Day 15

Dosing regimen for Cycle 1

All patients:

  Dose

0.8 mg/m2

0.5 mg/m2

0.5 mg/m2

  Cycle length

21 days*

Dosing regimen for subsequent cycles depending on response to treatment

Patients who have achieved a CR or CRi:

  Dose

0.5 mg/m2

0.5 mg/m2

0.5 mg/m2

  Cycle length

28 days

Patients who have not achieved a CR or CRi:

  Dose

0.8 mg/m2

0.5 mg/m2

0.5 mg/m2

  Cycle length

28 days

•
See full prescribing information for instructions on reconstitution of lyophilized powder, and preparation and administration of reconstituted drug. (2.4)

DOSAGE FORMS AND STRENGTHS

For injection: 0.9 mg lyophilized powder in a single-dose vial for reconstitution and further dilution. (3)

CONTRAINDICATIONS

None (4)

WARNINGS AND PRECAUTIONS

•
Myelosuppression: Monitor complete blood counts; for signs and symptoms of infection; bleeding/hemorrhage; or other effects of myelosuppression during treatment; manage appropriately. (5.3)
•
Infusion related reactions: Monitor for infusion related reactions during and for at least 1 hour after infusion ends. (5.4)
•
QT interval prolongation: Obtain electrocardiograms (ECGs) and electrolytes at baseline and monitor during treatment. Monitor more frequently when using concomitant mediations known to prolong QT interval. (5.5)
•
Embryo-fetal toxicity: Can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception. (5.6, 8.1, 8.3)

ADVERSE REACTIONS

The most common (≥ 20%) adverse reactions, including laboratory abnormalities, in adult and pediatric patients are thrombocytopenia, pyrexia, neutropenia, infection, anemia, vomiting, leukopenia, hemorrhage, fatigue, nausea, febrile neutropenia, headache, transaminases increased, abdominal pain, and gamma-glutamyltransferase increased, and hyperbilirubinemia. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

USE IN SPECIFIC POPULATIONS

Lactation: Advise not to breastfeed. (8.2)

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 3/2024

Find BESPONSA™ medical information:

Find BESPONSA™ medical information:

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

BESPONSA™ Quick Finder

Prescribing Information
Download Prescribing Information

Health Professional Information

Highlights

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use BESPONSA™ safely and effectively. See full prescribing information for BESPONSA.

BESPONSA (inotuzumab ozogamicin) for injection, for intravenous use
Initial U.S. Approval: 2017

WARNING: HEPATOTOXICITY, INCLUDING HEPATIC VENO-OCCLUSIVE DISEASE (VOD) (ALSO KNOWN AS SINUSOIDAL OBSTRUCTION SYNDROME) and INCREASED RISK OF POST- HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) NON-RELAPSE MORTALITY

See full prescribing information for complete boxed warning.

•
Hepatotoxicity, including fatal and life-threatening VOD occurred in patients who received BESPONSA. (5.1)
•
A higher post-HSCT non-relapse mortality rate occurred in patients receiving BESPONSA (5.2)

RECENT MAJOR CHANGES

Indications and Usage (1)

3/2024

Dosage and Administration, Instructions for Reconstitution, Dilution and Administration (2.4)

3/2024

Warnings and Precautions, Hepatotoxicity, Including Hepatic Veno-occlusive Disease (VOD) (also known as Sinusoidal Obstruction Syndrome) (5.1)

3/2024

Warnings and Precautions, Increased Risk of Post-Transplant Non-Relapse Mortality (5.2)

3/2024

Warnings and Precautions, Myelosuppression (5.3)

3/2024

Warnings and Precautions, Infusion Related Reactions (5.4)

3/2024

Warnings and Precautions, QT Interval Prolongation (5.5)

3/2024

INDICATIONS AND USAGE

BESPONSA is a CD22-directed antibody and cytotoxic drug conjugate indicated for the treatment of relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients 1 year and older. (1)

DOSAGE AND ADMINISTRATION

•
Administer by intravenous infusion only. (2.1)
•
Pre-medicate with a corticosteroid, antipyretic, and antihistamine prior to all infusions. (2.2)
•
Dosing regimens for Cycle 1 and subsequent cycles, depending on the response to treatment, are shown below. See full prescribing information for dosing details. (2)
*
For patients who achieve a CR or a CRi, and/or to allow for recovery from toxicity, the cycle length may be extended up to 28 days (i.e., 7-day treatment-free interval starting on Day 21).

Day 1

Day 8

Day 15

Dosing regimen for Cycle 1

All patients:

  Dose

0.8 mg/m2

0.5 mg/m2

0.5 mg/m2

  Cycle length

21 days*

Dosing regimen for subsequent cycles depending on response to treatment

Patients who have achieved a CR or CRi:

  Dose

0.5 mg/m2

0.5 mg/m2

0.5 mg/m2

  Cycle length

28 days

Patients who have not achieved a CR or CRi:

  Dose

0.8 mg/m2

0.5 mg/m2

0.5 mg/m2

  Cycle length

28 days

•
See full prescribing information for instructions on reconstitution of lyophilized powder, and preparation and administration of reconstituted drug. (2.4)

DOSAGE FORMS AND STRENGTHS

For injection: 0.9 mg lyophilized powder in a single-dose vial for reconstitution and further dilution. (3)

CONTRAINDICATIONS

None (4)

WARNINGS AND PRECAUTIONS

•
Myelosuppression: Monitor complete blood counts; for signs and symptoms of infection; bleeding/hemorrhage; or other effects of myelosuppression during treatment; manage appropriately. (5.3)
•
Infusion related reactions: Monitor for infusion related reactions during and for at least 1 hour after infusion ends. (5.4)
•
QT interval prolongation: Obtain electrocardiograms (ECGs) and electrolytes at baseline and monitor during treatment. Monitor more frequently when using concomitant mediations known to prolong QT interval. (5.5)
•
Embryo-fetal toxicity: Can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception. (5.6, 8.1, 8.3)

ADVERSE REACTIONS

The most common (≥ 20%) adverse reactions, including laboratory abnormalities, in adult and pediatric patients are thrombocytopenia, pyrexia, neutropenia, infection, anemia, vomiting, leukopenia, hemorrhage, fatigue, nausea, febrile neutropenia, headache, transaminases increased, abdominal pain, and gamma-glutamyltransferase increased, and hyperbilirubinemia. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

USE IN SPECIFIC POPULATIONS

Lactation: Advise not to breastfeed. (8.2)

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 3/2024
Medication Guide

Health Professional Information

{{section_name_patient}}

{{section_body_html_patient}}

Resources

Didn’t find what you were looking for? Contact us.

MI Digital Assistant

Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.

Call 800-438-1985*

*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5PM ET Monday to Friday; excluding holidays.

Medical Inquiry

Submit a medical question for Pfizer prescription products.

Report Adverse Event

Pfizer Safety

To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:

Pfizer Safety Reporting Site

*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.

If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.

FDA Medwatch

You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.